Sugi Predict

Sugi Predict / Compounds / SCHEMBL2822013

SCHEMBL2822013

SCHEMBL2822013

Cc1ccc(S(=O)(=O)OCCCCNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 13/20 0.60
▸ CA2 P00918 13/20 0.60
▸ CA12 O43570 7/20 0.60
▸ CA9 Q16790 7/20 0.60
▸ TDP1 Q9NUW8 1/20 0.47
▸ CCNC P24863 1/20 0.46
▸ CDK8 P49336 1/20 0.46
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29040417 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL10191081 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL29040410 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL4640090 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL16930099 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL23835564 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL29040473 0.99 CA1 (0.61) CA1CA2CA12CA9TDP1
SCHEMBL487585 0.96 CA1 (0.59) CA1CA2CA12CA9TDP1
SCHEMBL22326324 0.93 CA1 (0.56) CA1CA2CA12CA9TDP1
SCHEMBL22326171 0.93 CA1 (0.56) CA1CA2CA12CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-12552775-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2026-02-17 — — US disclosed
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
EP-4584265-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2025-07-16 — — EP disclosed
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-03-06 — — US disclosed
EP-4469448-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2024-12-04 — — EP disclosed
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 — — US disclosed
CN-118119609-A Imidazole derivatives and their use as antibiotics 豪夫迈·罗氏有限公司 2024-05-31 — — CN disclosed
US-20240101534-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-03-28 — — US disclosed
WO-2024052690-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
WO-2007122156-A1 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2007-11-01 — — WO disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 — — US disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 — — US disclosed
CN-1495184-A Substituted purine derivative, its preparation method, application and composition containing it �ճ�˹�عɷݹ�˾ 2004-05-12 — — CN disclosed
US-6723727-B1 VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS HOECHST AKTIENGESELLSCHAFT (DE) 2004-04-20 — — US disclosed
CN-1101816-C Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 2003-02-19 — — CN disclosed
CN-1193623-A Substituted purine derivatives, their preparation, their use and compositions containing them HOECHST AG (DE) 1998-09-23 — — CN disclosed
CN-1107151-A Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders SANKYO CO (JP) 1995-08-23 — — CN disclosed
CN-1028527-C Process for preparing coumarin derivatives SANKYO CO (JP) 1995-05-24 — — CN disclosed
CN-1049662-A Coumarin derivative, preparation thereof and application thereof in treating cerebrovascular disorder SANKYO CO (JP) 1991-03-06 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101534-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 CA1 4655/4885CA2 4600/4885CA12 3780/4885
US-12552775-B2 Compounds and uses thereof SMARCC1, SMARCC2, CHD1 CA1 4239/4885CA2 3407/4885CA12 4197/4885
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF NCOR2, NSD2, NCOR1 CA1 4590/4885CA2 4561/4885CA12 4129/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 CA1 431/4885CA2 181/4885CA12 1457/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 CA1 4498/4885CA2 3900/4885CA12 4051/4885
US-20070004742-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A CA1 4650/4885CA2 4304/4885CA12 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.